For the quarter ending 2025-09-30, FHTX made $8,153K in revenue. -$15,781K in net income. Net profit margin of -193.56%.
| Income Statement | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 8,153 | 3,953 | 7,808 | 6,888 |
| Research and development | 20,002 | 23,021 | 24,689 | 23,797 |
| General and administrative | 6,652 | 7,032 | 6,971 | 7,325 |
| Impairment of long-lived assets | 0 | 0 | - | 2,398 |
| Total operating expenses | 26,654 | 30,053 | 31,660 | 33,520 |
| Loss from operations | -18,501 | -26,099 | -23,852 | -26,632 |
| Interest income | 2,032 | 2,768 | 3,495 | 2,870 |
| Other income, net | 620 | 1,073 | 1,235 | 783 |
| Total other income, net | 2,652 | 3,840 | 4,730 | 3,653 |
| Loss before income taxes | - | -22,259 | -19,122 | -22,979 |
| Net loss | -15,849 | -22,259 | -19,122 | -22,979 |
| Unrealized gains (losses) on marketable securities | 68 | 52 | 698 | 159 |
| Total other comprehensive gain (loss) | 68 | 52 | 698 | 159 |
| Total comprehensive loss | -15,781 | -22,207 | -18,424 | -22,820 |
| Net loss per share attributable to common stockholdersbasic (in dollars per share) | -0.25 | -0.41 | -0.31 | -0.45 |
| Net loss per share attributable to common stockholdersdiluted (in dollars per share) | -0.25 | -0.41 | -0.31 | -0.45 |
| Weighted average common shares outstandingbasic (in shares) | 63,029,293 | -29,641,863 | 62,602,848 | 51,580,310 |
| Weighted average common shares outstandingdiluted (in shares) | 63,029,293 | -29,641,863 | 62,602,848 | 51,580,310 |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)